書籍詳細

表紙

P.3 掲載の参考文献

• 1) Krakoff, I. H.:The present status of cancer chemotherapy. The Medical Clinics of North America 55:683-701, 1971.
  pubmed

• 2) 許泰一, 土肥博雄:急性非リンパ性白血病の化学療法. カレントテラピー 6:578-582, 1988.

• 3) 尾山 淳, 森田皓三, 須知泰山・他:悪性リンパ腫の予後因子. 癌の臨床 34:705-713, 1988.

• 4) 山田龍作, 佐藤守男, 野村尚三・他:肝細胞癌に対する動脈塞栓療法-7年9か月, 529例の成績. 日本癌治療学会誌 21:1104-1106, 1986.

• 5) 犬山征夫:頭頸部癌に対する化学療法. 医学のあゆみ 141:661-665, 1987.
  Medical*Online

• 6) Ozols, R. F., and Young, R. C.:Ovarin cancer. Current Problems in Cancer 11:61-122, 1987.

• 7) 古武敏彦, 三木恒治:睾丸腫瘍に対する化学療法後のSalvage Surgery. 癌と化学療法 4(5) Part II :1671-1979, 1987.

• 8) Aisner, J., Alberto, P., Comis, P. et al.:Role of chemotherapy in small cell lung cancer. A Concensus report of the IASLC Workshop. Cancer Treat Rept. 67:37, 44, 1983.

• 9) 福岡正博, 根来俊一:進行性非小細胞癌の化学療法. 医学のあゆみ 141:685-689, 1987.

I 基礎からみた肺癌化学療法発展のための条件

P.15 掲載の参考文献

• 1) Hamburger, A. W. and Salmon, S. E.:Primary bioassay of human tumor stem cell. Science 197:461, 1977.
  pubmed

• 2) Shimizu, E., Saijo, N., Kanzawa, F. et al:Correlation between drug sensitivity determined by clonogenic cell assay and clinical effect of chemotherapy in patients with primary lung cancer. Jpn. J. Cancer Res. (Gann) 75:1030, 1984.

• 3) 藤本修一:癌の化学療法-治療成績向上のためのアプローチ(I) -. 薬事新報 No. 1427:261, 1987.

• 4) Ihde, D. C.:Personal communication
  pubmed

• 5) Gazdar, A. F., Tsai, C. M., Park, J. G. et al:Neurocrine differentiation in non-small cell lung cancer. Proceedigs of the First International Symposium of the Foundation for Promotion of Cancer Research 32, 1988.

• 6) Takahashi, H., Sasaki, Y. et al:In vitro colony inhibition of Carboplatin against stomack and lung cancer cell lines in comparison with Cisplatin. Cancer Chemother. Pharmacol. 19:197, 1987.

• 7) Scheithauer, W., Clark, G. M., Salmon, S. E. et al:Model for estimation of clinically achievable plasma concentrations or investigational anticancer drugs in man. Cancer Treat. Rep. 70:1379, 1986.
  pubmed

• 8) Horiuchi, N. et al:Cancer Chemother. Pharmacol. (in press)

• 9) Hong, W. S., Saijo, N., Sasaki, Y. et al:Eatablishment and characterization of Cisplatin-resistant sublines of human lung cancer cell lines. Int. J. Cancer 41:462, 1988.
  pubmed

P.24 掲載の参考文献

• 1) Chen, C., Chin, J. E., Ueda, K. et al:Internal duplication and homology with bacterial transport protein in the mdr1 (p-glycoprotein) gene from multidrug-resistant human cells, Cell 47:381-389, 1986.

• 2) Garlach, J. H., Endicott, J. A., Juranka, P. F. et al:Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 324:485-489, 1986.

• 2) Hamada, H. and Tsuruo, T.:Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 83:7785-7789, 1986.
  pubmed

• 3) Sugimoto, Y. and Tsuruo, T.:DNA-mediated transfer and cloning of a human multidrug-resistant gene of Adriamycin-resistant myelogenous leukemia K562, Cancer Res. 41:2620-2625, 1987.

• 5) Thiebaut, F., Tsuruo, T., Hamada, H. et al:The location of the multidrug resistance gene-product P-glycoprotein in normal tissues. Proc. Natl . Acad. Sci. USA 84:7735-7738, 1987.
  pubmed

• 6) Hamada, H. and Tsuruo, T.:Purification of the 170- to 180- kilodalton membrane glyco-protein associated with multidrug-resistance:The 170- to 180-kilodalton membrane glyco-protein is an ATPase. J. Biol. Chem. 263:1454-1458, 1988.

• 7) Hamada, H., Hagiwara, K., Nakajima, T. et al:Phosphorylation of the Mr 170000 to 180000 glycoprotein specific to multidurg-resistant tumor cells:Effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res. 47:2860-2865, 1987.

• 8) Tsuruo, T., Iida, H., Tsukagoshi, S. et al:Overcoming of vincristine resistance in P388 leukemia, in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967-1972, 1981.
  pubmed

• 9) Tsuruo, T., Iida, H., Tsukagoshi, S. et al:Increased accumulation of vincristine and Adri-amycin in drug resistant tumor cells following incubatiion with calcium antagonists and calmodulin inhibitors. Cancer Res. 42:4730-4733, 1982.

• 10) Tsuruo, T., Matsuzaki, T., Matsushita, M. et al:Antitumor effects of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21:71-74, 1988.
  pubmed

• 11) Tsuruo, T., Yamori, T., Naganuma, K. et al:Characterization of metastatic clones derived from a metastatic variant of mouse colon adenocarcinoma 26. Cancer Res. 43:5437-5442, 1983.
  pubmed

• 12) Tsuruo, T., Kawabata, H., Iida, H. et al:Tumor induced platelet aggregation and growth promoting factors as determinants for successful tumor metastasis. Clin. Expl. Metastasis 4:25-33, 1986.

• 13) Sugimoto, Y., Oh-hara, T., Watanabe, M. et al:Acquisition of metastatic ability in hybrid-omas between two low metastatic clones of murine colon adenocarcinoma 26 defective in either platelet-aggregating activity or in vivo growth potential. Canctr Res. 47:4396-4401, 1987.

• 14) Yamori, T., Iida, H., Tsukagoshi, S. et al:Growth stimulating activity of lung extract on lung-colonizing colon 26 clones and its partial characterization. Clin. Expl. Metastasis 6:131-139, 1988.

P.32 掲載の参考文献

• 1) Nishimura, S. and Sekiya, T.:Human cancer and cellular oncogenes. Biochem. J. 243:313-327, 1987.
  pubmed

• 2) Rodenhuis, S., Wetering, M. L, Mooi, W. J. et al:Mutational activation of the K-ras oncogene, a possibie pathogenetic factor in adenocarcinoma of the lung. N. Engl. J. Med. 317:929-935, 1987.

• 3) Bos, J. L., Fearon, E. R., Hamilton, S. R. et al:Prevalence of ras gene mutations in human colorectal cancers. Nature 327:293-297, 1987.
  pubmed

• 4) Farr, C. J., Saiki, R. K., Erlich, H. A. et al:Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc. Natl. Acad. Sci. USA 85:1629-1633, 1988.
  pubmed

• 5) Almoguera, C., Shibata, D., Forrester, K. et al:Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554, 1988.
  pubmed

• 6) Liotta, L. A.:H-ras p 21 and the metastatic phenotype. J. Natl. Cancer Inst. 80:468-469, 1988.

• 7) Brooks, B. J., Battey, J., Nau, M. M. et al:Amplification and expression of the myc gene in small-cell lung cancer. Advance in Viral Onocology 7:155-172, 1987.

• 8) Yokota, J., Tsunetsugu-Yokota, Y., Battifora, H. et al:Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation. Science 231:261-265, 1986.
  pubmed

• 9) Little, C. D., Nau, M. M., Carney, D. N. et al:Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306:194-196, 1983.

• 10) Nau, M. M., Brooks, B. J., Carney, D. N. et al:Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc. Natl. Acad. Sci. USA 83:1092-1096, 1986.

• 11) Nau, M. M., Brooks, B. J., Battey, J. et al:L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature 318:69-72, 1985.

• 12) Wong, A. J., Ruppert, J. M., Eggleston, J. et al:Gene amplificationof c-myc and N-myc in small cell carcinoma of the lung. Science 233:461-464, 1986.

• 13) Yokota, J., Wada, M., Yoshida, T. et al:Heterogeneity of lung cancer cells with respect to the amplification and rearrangement of myc family oncogenes. Oncogene 2:607-611, 1988.

• 14) Yoshimoto, K., Shiraishi, M., Hirohashi, S. et al:Rearrangement of the c-myc gene in two giant cell carcinomas of the lung. Jpn. J. Cancer Res. 77:731-735, 1986.

• 15) Naylor, S. L, Johnson, B. E., Minna, J. D. et al:Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 329:451-454, 1987.
  pubmed

• 16) Kok, K., Osinga, J., Carritt, B. et al:Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 330:578-581, 1987.
  pubmed

• 17) Brauch, H., Johnson, B., Hovis, J. et al:Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. N. Engl. J. Med. 317:1109-1113, 1987.
  pubmed

• 18) Yokota, J., Wada, M., Shimosato, Y. et al:Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc. Natl. Acad. Sci. USA 84:9252-9256, 1987.
  pubmed

• 19) Yokota, J., Akiyama, T, Fung, Y-K. T. et al:Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene (in press)

• 20) Shiraishi, M., Morinaga, S., Noguchi, M. et al:Loss of genes on the short arm of chromosome 11 in human lung carcinomas. Jpn. J. Cancer Res. (Gann) 78:1302-1308, 1987.
  pubmed

• 21) Hendler, F. J. and Ozanne, B. W.:Human squamous cell lung cancers express increased epidermal growth factor receptors. J. Clin. Invest. 74:647-651, 1984.
  pubmed

• 22) Veale, D., Ashcroft, T., Marsh, C. et al:Epidermoid growth factor receptors in non-small cell lung cancer. Br. J. Cancer 55:513-516, 1987.

P.40 掲載の参考文献

• 1) McDonald, T. J., Jornvall, J. H., Nilssen, G. et al:Characterization of a gastrin-releasing peptide from porcine nonantral tissue. Biochem. Biophys. Res. Commun. 90:227-233, 1979.

• 2) Rosengurt, E. and Sinnert-Smith, J.:Bombesin Stimulation of DNA Synthesis and cell division in cultures of Swiss 3T3 cells. Proc. Nath. Acad. Sci. USA 89:2936-2940, 1983.

• 3) Willey, J. C., Ledner, J. F. and Harris, C. C.:Bombesin and the C-terminal tetradecapeptide of gastrin-releasing peptides are growth factors for normal human bronchial epithelial cells. Exp. Cell Res. 153:245-248, 1984.

• 4) Weber, S., Zuckerman, J. E., Bostwick, D. G. et al:Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro. J. Clin. Invest. 75:306-309, 1985.
  pubmed

• 5) Cuttita, F., Carney, D. N. and Mulshine, J.:Bombesin-live peptides can function as autocrine growth factors in human small-cell lung cancer. Nature (Lond.) 316:823-826, 1985.

• 6) Moody, T. W., Pert, C. B., Gazdar, A. F. et al:High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science 214:1246-1248, 1981.
  pubmed

• 7) Iwanaga, T.:Gastrin-releasing peptide (GRP) /bombesin-like immunoreactivity in the neurons and paraneurons of the gut and lung. Biomed. Res. 4:93-103, 1983.

• 8) Anastasi, A., Erspamer, V. and Bucci, M.:Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the European amphibians Bompina and Alytes. Experentia 27:166-168, 1971.

• 9) Erspamer, V.:The tachykinin peptide family. TINS 4:267-269, 1981.

• 10) Growcott, J. W., Jamiesen, A., Tarpey, A. V. et al:Further evidence for multiple tachykinin receptors. Eur. J. Pharmacol. 86:59-64, 1983.

• 11) Zachary, I, and Rozengurt, E.:High-affinity receptors for peptides of the bombesin family in Swiss 3T3 cells. Proc, Natl. Acad. Sci. USA 82:7616-7620, 1985.
  pubmed

• 12) Woll, P. J. and Rozengurt, E.:[D-Arg1, D-Phe5, D-Trp7, 9, Leu11] substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc. Nath. Acad. Sci. USA 85:1859-1863, 1988.

• 13) Yanaihara, N., Yanaihara, C., Mochizuki, T. et al:Immunoreactive GRP. Peptides 2(Suppl. 2) :185-191, 1981.

• 14) Yamaguchi, K., Abe, K., Kameya, T. et al:Production and molecular size heterogenity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. Cancer Res. 43:3932-3939, 1983.
  pubmed

• 15) Bepler, G., Carney, D. N. Gazdar, A. F. et al:In vitro growth inhibition of human small cell lung cancer by physalaemin. Cancer Res. 47:2371-2375, 1987.
  pubmed

• 16) Erspamer, V., Anastasi, A., Bertaccini, G. et al:Structure and pharmacological actions of physalaemin, the main active polypeptide of the skin of physaluenus fuscumaculatus. Arch. Biochem. Biophys. 108:341-348, 1964.

• 17) Lazarus, L. H., Linnolia, R. L., Hernandez, O. et al:A neuropeptide in mammalian tissues with physalaemin-like immunoreactivity. Nature (Lond.) 287:555-558, 1980.

• 18) Nilsson, J., Von Euler, A. M. and Dalsgaart, C-J.:Stimulation of connective tissue cell growth by substance P and substance K, Nature (Lond) 315:61-63, 1985.

• 19) Veber, D. F., Saperstein, R. Nutt, R. F. et al:A super active cyclic hexapeptide analog of somatostatin. Life Sci. 31:1133-1140, 1982.

• 20) Yanaihara, N., Yanaihara, C., Hoshino, M. et al:Immunochemical and biochemical properties of purposely designed synthetic peptides. Annals of the N. Y. Acad. of Science 527:29-43, 1988.

• 21) Yanaihara, N., Yanaihara, C., Nokihara, K., et al:Immuuochemical study on PHI/PHM with use of synthtic peptides. Peptides 5:247-254, 1984.

• 22) Yanaihara, C., Hashimoto, Y., Takeda, Y. et al:PHI structaral requirements for potentiation of glucose-induced insulin release. Peptides 7(Suppl 1) :83-88, 1986.

• 23) Tatemoto, K., Rokaeus, A., Jornvall, H. et al:Galanin a novel biologically active peptide from porcine intestine. FEBS Lett. 164:124-128, 1983.
  pubmed

• 24) Rokaeus, A., Melander, T., Hokfelt, T. et al:A galanin-like peptide in the central nervous system and intestine of the rat, Neurosci Lett. 47:161-166, 1984.
  pubmed

• 25) Ahren, R., Arkhammar, P., Berggren, P. O. et al:Galanin inhibits glucose-stimulated insulin release by a mechanism involving hyperpolarization and Iowering of cytoplasmic free Ca2+ concentration. Biochem. Biopheps. Res. Commun. 140:1059- 1063, 1986.

• 26) 矢内原昇, 矢内原千鶴子, 井上 孝・他:腫瘍と発癌遺伝子産物. ホルモンと臨床 35:161-165, 1987.

P.53 掲載の参考文献

• 1) Souhami, R. L., Beverley, P. C. L. and Bobrow, L. G.:Antigens of small-cell lung cancer, First International Workshop. Lancet 2:325-326, 1987.

• 2) Takahashi, T., Ueda, R. Song, X. et al.:Two novel cell surface antigens on small cell lung carcinoma defined by mouse monoclonal antibodies NE-25 and PE--35. Cancer Res. 46:4770-4775, 1968.

• 3) Ueda, R., Takahashi, T., Watanabe, H. et al.:Serological and biochemical analysis of four antigens associated with small cell lung cancer., Lung cancer:in press

• 4) Watanabe, H., Takahashi, T., Ueda, R. et al.:Antigenic phenotype and biological characteristics of two distnct sublines derived from a small cell lung carcinoma cell lines. Cancer Res. 48:2544-2549, 1988.

• 5) Carney, D. N., Gazdar, A. F., Bepler, G. et al.:Establishment and identification of small cell lung cancer lines having classic and variant features. Cancer Res. 45:2913-2923, 1985.
  pubmed

• 6) World Health Organization. The WHO histlogical typing of lung tumors. Ed. 2. Am. J. Clin. Pathol. 78:123-136, 1982.

• 7) Yesner, R, :Classification of lung-cancer histology. N Engl. J. Med. 312:652-653, 1985.
  pubmed

• 8) Gazdar, A. F., Carney, D. N, Nau, M. M. et al.:Characterization of varaint subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 45:2924-2930, 1985.

• 9) Abeloff, M. D., Egglestone, J. C., Mendelsohn, G. et al.:Changes in morphologic and biochemical characteristics of small cell carcinoma of the lung. Am. J. Med. 66:757-764, 1979.

• 10) Graziano, S. L., Cowan, B. Y., Carney, D. N. et al.:Small cell lung cancer cell line derived from a primary tumor with a characteristic deletion of 3p. Cancer Res. 47:2148-2155, 1987.
  pubmed

• 11) Goodwin, G. and Baylin, S. B.:Relationships between neuroendocrine differentiation and sensitivity to gamma-radiation in culture line OH-1 of human small cell lung carcinoma. Cancer Res. 42:1361-1367, 1982.
  pubmed

• 12) Goodwin, G., Shaper, J. H., Abeloff, M. D. et al.:Analysis of cell surface proteins delineates a differentiation pathway linking endocrine and nonendocrine human lung cancers. Proc. Natl. Acad. Sci. USA 80:3807-3811, 1983.
  pubmed

• 13) Whang-Peng, J., Kao-Shan, C. S., Lee, E. C. et al.:A specific chromosome defect associated with human small-cell lung cancer:Deletion 3p (14-23) . Science 215:181-182, 1982.
  pubmed

• 14) Whang-Peng, J., Bunn, P. A., Kao-Shan, EC. et al.:A non-random chromosomal abnormality, del3p (14-23) in human small cell lung cancer. Cancer Genet. Cytogenet. 6:119- 134, 1982.

• 15) Little, C. D., Nau, M. M., Carney, D. N. et al.:Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306:194-196, 1983.

• 16) Schwab, M., Alitalo, K., Klempnauer, K. -H. et al.:Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305:245-248, 1983.

• 17) Kohl, N. E., Gee, C. E. and Alt, F. W.:Activated expression of the N-myc gene in human neuroblastoma and related tumors. Science 226:1335-1337, 1984.

• 18) Nau, M. M., Brooks, B. J., Batty, J. et al.:L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature 318:69-73, 1985.

• 19) Souhami, R. L., Finn, G., Gregory, W. M. et al.:High dose cyclophosphamide in small cell carcinoma of the lung. J. Clin. Oncol. 3:958-963, 1985.
  pubmed

• 20) Mosmann, T.:Rapid colorimetric assay for cellular growth and surviva';application to proliferation and cytotoxicity assay. J. Immunol. Methods 65:55-63, 1983.

• 21) Hamburger, A. W. and Salmon, S. E.:Primary bioassay of human tumor stem cells. Science 197:461-463, 1977.
  pubmed

• 22) Sao, H., Morishima, Y., Ueda, R. et al.:Serological study for in vitro use of monoclonal antibody for autologous bone marrow transplantation in null cell-type acute lymphocytic leukemia. Jpn. J. Cancer Res. (Gann) 76:1212-1221, 1985.
  pubmed

• 23) Morishima, Y., Sao, H., Ueda, R. et al.:Preliminary clinical trial of autologous bone marrow transplantation after in vitro monoclonal antibody and complement treatment in null cell-type acute lymphocytic leukemia. Jpn. J. Cancer Res. (Gann) 76:1222-1229, 1985.
  pubmed

II 他領域からみた肺癌化学療法への提言

P.66 掲載の参考文献

• 1) National Tuberculosis Institute, Bangalore:Tuberculosis in a rural population of South India. A Five-year epidemiological study. Bull. Wld. Hlth. Org. 51:473-488, 1974.

• 2) 砂原茂一:日本結核病学会における結核研究の歩み, 化学療法. 結核 50:528-534, 1975.

• 3) 金井興美:結核化学療法100年の展望, (その1) 結核化学療法剤開発のあゆみ. 結核 57:643-651, 1982

• 4) Medical Research Council investigation:Streptomycine treatment of pulmonary tuberculosis. Br. Med. J. 2:769-782, 1948

• 5) Medical Research Council investigation:The prevention of streptomycin resistance by combined chemotherapy. Br. Med. J. 1:1157-1162, 1952
  pubmed

• 6) Tucker, W. B.:The evolution of the cooperative studies in the chemotherapy of tuberculosis of Vetrans Adminstration and Armed Force of the U. S. A. -an account of the physician in clinical pharmacology-. Advance in Tuberc. Research. 10:1-68, 1960.

• 7) American Trudeau Society:Changing concepts and modern treatment of tuberculosis. Amer. Rev. Tuberc. 70:930-948, 1954

• 8) 岩崎龍郎:肺結核症の化学療法に関する臨床的並びに病理形態学的研究. 結核 30 (増刊号) :1-12, 1955

• 9) 文部省科学研究費「化学療法による結核治癒機転」研究班:化学療法を目標とした肺結核の病型分類. 日本医事新報 1752:37-38, 1957, 化学療法による肺結核の病状経過判定. 日本医事新報 1770:20-22, 1958.

• 10) Dubos, R. T. and Middlebroook, G.:Media for tubercle bacilli. Amer. Rev. Tuberc. 56:334-345, 1947.

• 11) Youmans, G. P. and Yomans, A. R.:The relation between the size of the infecting dose of tubercle bacilli and the survival time of mice. Amer. Rev. Tuber. 64:534-540, 1951.

• 12) 国立療養所化学療法共同研究班:「結核化学療法の対照試験 (1957-1966) 」. 厚生省国立療養所化学療法共同研究班編, 国立療養所東京病院, 東京, pp. 1-326, 1970.

• 13) 国立療養所化学療法共同研究班:「結核化学療法の対照試験2. (1967-1976) 」. 厚生省国立療養所化学療法共同研究編, 国立療養所東京病院, 東京, pp. 1-103, 1980.

• 14) 島村喜久治:第41回結核病学会シンポジウムII, 各種結核化学療法の比較検討- 2. 国立療養所化学療法共同研究班の成績から. 結核 41:436-442, 1970.

• 15) 堂野前維摩卿, 山本和男:空洞の化学療法, 「結核の化学療法」(北本治, 藤田真之助編) , 医学 書院, 東京, pp. 214-243, 1959.

• 16) 国立療養所化学療法共同研究班:無作為割当による肺結核化学療法方式の比較, 第2次共同研究報告, INH大量, SMとINHの切り換えおよびINH誘導体の意義についての検討. 日本胸部臨床 21:768-780, 1962;21:860-875, 1952.

• 17) 国立療養所化学療法共同研究班:無作為割当による肺結核化学療法方式の比較, 第4次共同研究報告, くるくる療法, 皮質ホルモン併用療法, INH大量療法, PAS少量療法の評価. 日本胸部臨床 23:585-601, 1964.

• 18) 国立療養所化学療法共同研究班:二次薬治療における1剤, 2剤および3剤方式の比較-第7次B研究. 結核 43:199-207, 1968.

• 19) 国立療養所化学療法共同研究班:Rifampicinを使用した初回治療の成績-第13次国療化研A研究-. 結核 48:235-245, 1973.

• 20) East Africca/Brit. Mrd. Rsear. Councils:Controlled clinical trial of four short-course (6-months) regimen of chemotherapy for treatment of pulmonary tuberculosis (1st-3rd report) . Lancet 1:1079-1085, 1972;1:1331-1338, 1973;2:237-240, 1974.

• 21) 日本結核病学会治療専門委員会:肺結核化学療法の期間に関する見解. 結核 55:189-193, 1980.

• 22) 亀田和彦, 岩井和郎, 岩崎龍郎・他:肺結核の切除病巣内結核菌培養に関する共同研究. 結核 45:143-151, 1970.

• 23) Fox, W. and Mitchison, D. A.:Short-course chemotherapy for pulmonary tuberculosis. Am. Rev. Respir. Dis. 111:325-353, 1975. Fox, W.:第53回日本結核病学会招請講演, 短期化学療法の現状, 特に処方と機序に関連して. 結核 53:503-509, 1978.

• 24) 木野智慧光:肺結核の初回治療. 「内科Mook, 36, 結核」, 金原出版, pp. 111-120, 1987.

• 25) Mitchison, D.:Response of patients with initial drug resistance to short-course chemotherapy. Bull. Int. Union Tuber. 60:38-39, 1985.

• 26) Grosset, J.:The saterilising value of rifampicin and pyrazinamide in experimental short- course chemotherapy. Tubercle 59:287-297, 1978.

P.77 掲載の参考文献

• 1) DeVita, V. T., Serpick, A. A., Carbone, P. P. et al:Combination chemotherapy in the treatment of advanced Hodgkins disease. Ann. Intern. Med. 73:881-895, 1970.
  pubmed

• 2) Longo, D. L, Young, R. C., Wesley, M et al:Twenty years of MOPP chemotherapy for Hodgkin's disease. J. Clin. Oncol. 4:1295-1306, 1986.
  pubmed

• 3) Skipper. H. E., Schabel, F. M. and Wilcox, W. S, :Experimental evaluation of potencial anticancer, agents. XII. On the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother. Rep. 35:1-111, 1964.

• 4) Coltman, C. A.:Chemotherapy of advanced Hodgkin's disease. Semin. Oncol. 7:155-173, 1980.
  pubmed

• 5) Bonadonna, G., Valagussa, P. and Santoro, A.:Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann. Intern. Med. 104:739-746, 1986.

• 6) Connors, J. M. and Klimo, P.:MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease. Semin. Hematol. 24 (Suppl 1) :35-40, 1987.

• 7) Coleman, M., Gerstein, G., Topilow, A. et al:Advancesof chemotherapy for large cell lymphoma. Semin. Hematol. 24(Suppl 1) :8-20, 1987.

• 8) DeVita, V. T.:The evolution of chemotherapy of lymphomas of adults. LEUKEMIA 1:467-485, 1987.
  pubmed

• 9) DeVita, V. T., Canellos, G. P., Chabner, B. et al:Advanced diffuse histiocytic lymphoma:a potentially curable disease. Lancet 1:248, 1975.
  pubmed

• 10) 多田敦彦, 大熨泰亮, 林 恭一・他:びまん性大細胞型非ホジキンリンパ腫に対する多剤併用療法の治療成績-Adriamycin を含む多剤併用療法の有用性について-癌と化学療法 14:2692-2696, 1987.
  Medical*Online

• 11) 水田潤, 吉田光雄, 多田敦彦・他:中高悪性度non-Hodgkinリンパ腫(NHL) に対するCHOP-B/POEM-B交替療法の試み. 第29回日本臨床血液学会総会抄録集 p. 221, 1987.

• 12) Goldie, J. H. and Coldman, A. J.:A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63:1727-1733, 1979.
  pubmed

• 13) Goldie, J. H., Coldman, A. J. and Gudauskas, G. A.:Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat. Rep. 66:439-449, 1982.
  pubmed

• 14) Riordan, J. R. and Ling, V.:Genetic and biochemical characterizationof multidrug resistance. Pharmac. Ther. 28:51-75, 1985.

• 15) Wittes, R. E., Hopfan, S. and Wittes, J. B. et al:Oat cell carcinoma of the lung:Combination chemotherapy with cyclophosphamide, vincristine and procarbazine. Clin. Bull. 7:21-24, 1977.

• 16) Murray, N.:The importance of dose and dose intensity in Iung cancer chemotherapy. Semin. Oncol. 14(Supple 4) :20-28, 1987.

• 17) Shah, A., Murray, N., Osoba, D. et al:CODE-A dose-intense chemotherapy regimen for lung cancer. Proc. ASCO 7:209, 1988.

P.88 掲載の参考文献

• 1) 正岡 徹:骨髄移植. 日本内科学会誌 76:654-657, 1987.

• 2) Teshima, H. et at:Interstitial pueumonitis in allogeneic bone marrow transplantation. Bone Marrow Transplantation 1:179, 1986.

• 3) Nakamura, H. et al:Significance of Graft versus Host disease in allogeneic bone marrow transplantation. Acta Haem. JPN. 50:1627-1633, 1987.

• 4) 石原重彦・他:自家骨髄移植による神経芽細胞腫の治療. 小児外科 19(11) :1413-1421, 1987.

• 5) Masaoka, T. et al:Administration of human urinary colony stimulating factor after bone marrow transplantation. Bone Marrow Transplantation 3:121-127, 1988.
  pubmed

• 6) 柴田弘俊・他:骨髄移植における人尿由来コロニー刺激因子(CSF-Hu) の二重盲検法による効果の検討. 今日の移植. 印刷中, 1988.

• 7) Abrams, R. A. et al:Bone marrow auto transplantation in man. Lancet (oct.) 25:960-962, 1986.

III 肺癌化学療法の現状打破のための条件

P.112 掲載の参考文献

• 1) 厚生省大臣官房統計情報部人口動態統計課:人口動態, 1985.

• 2) DeVita, V. T. Jr.:Principle of chemotherapy. Cancer Principle and Practice of oncology vol. I, pp. 257-285, J. B. Lippincott Company, Philadelphia, 1985.

• 3) Green, R. A., Humphrey, E., Close, H. et al:Alkylating agents in bronchogenic carcinoma. Am. J. Med. 46:516-525, 1969.
  pubmed

• 4) Aisner, J., Alberto, P., Bitran, J. et al:Role of chemotherapy in small cell lung cancer:A consensus report of the international association for the study of lung cancer workshop. Cancer Treat. Rep. 67:37-43, 1983.

• 5) Gralla, R. J., Casper, E. S., Kelsen, D. P. et al:Cisplatin and vindesin combination chemotherapy for advanced carcinoma of the lung:A randomized trial investigating two dosage schedules. Ann. Intern. Med. 95:414-420, 1981.

• 6) Rapp, E., Pater, J., Willan, A et al:A comparison of best supportive care to two regimens of combination chemotherapy in the management of advanced non-small cell lung cancer. A report of a Canadian multicentre trial. Proc. Am. Soc. Clin. Oncol. 6:168, 1987.

• 7) 富永祐民:Cox の重回帰型生命表法 (比例ハザードモデル) の理論と応用. 治療効果判定のための実用統計学, pp. 123-134, 蟹書房, 東京, 1985.

• 8) Stanley, K. E.:Prognostic factors in lung cancer. Lung Cancer, pp. 41-66, Churchill Livingstone, New York, 1985.

• 9) O'Connell, J. P., Kris, M. G., Gralla, R. J. et al:Analysis of factors predicting outcome in 350 patients with stage III non-small cell lung cancer receiving high-dose cisplatin/ vinca alkaloid regimens. Proc. Am. Soc. Clin. Oncol. 4:190, 1985.

• 10) φsterlind K.:Prognostic factors in small cell lung cancer:An analysis of 874 consecutive patients. Lung Cancer 3, pp. 129-152, Martinus Nijhoff, Boston, 1985.

• 11) Souhami, R. L., Bradbury, I., Geddes, D. M. et al:Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res. 45:2878-2882, 1985.
  pubmed

P.123 掲載の参考文献

• 1) Holmes, E. C., Gail, M.:Surgical adjuvant therapy for stage ll and stage III adenocarcinoma and large cell undifferentiated carcinoma. J. Clin. Oncol. 4:710-715, 1986.

• 2) Ayoub, J., Duranceau, A., Lorange, A. et al:Effectiveness of adjuvant chemotherapy in operable non-small cell lung cancer [abstruct]. In Proceedings of the IV World Conference on Lung Cancer, Toronto, Canada, p. 32, 1985.

• 3) Kris, M. G., Gralla, R. J., Martini, N. et al:Preoperative and adjuvant chemotherapy in locally advanced non-small cell lung cancer. Surg. Clin. North. Am. 67:1051-1059, 1987.
  pubmed

• 4) Morrison, R., Deeley, T. J. and Cleland, W. P.:The treatment of carcinoma of the bronchus:A clinical trial to compare surgery and supervoltage radiotherapy. Lancet 683-684, 1963.

• 5) Shield, T. W., Higgins, G. A., Lawton, R. et al:Preoperative x-ray therapy as an adjuvant in the treatment of bronchogenic carcinoma. J. Thorac. Cardiovasc Surg. 59:49-61, 1970.

• 6) Paulson, D. L.:The importance of defining Iocation and staging of superior pulmonary sulcus tumor Ann. Thorac. Surg. 15:549-551, 1973.
  pubmed

• 7) Skarin, A., Veeder, M., Malcolm, A. et al:Chemotherapy (CAP) prior to radiotherapy (RT) and surgery in marginally resectable non-small cell lung cancer (NSCLC) [abstruct]. Proc. Am. Soc. Clin. Oncl. 1:143, 1982.

• 8) Folman, R., Rosman, M. and Auerbach, S.:Mitomycin-C, vinblastine and cis-platinum in the combined modality treatment of non-small cell lung cancer [abstruct]. Proc. Am. Soc. Clin. Oncol. 3:232, 1984.

• 9) Spain, R., Amderson, P., Speer, J. et al:Improved survival with mitomycin-C, cis-platinum and continuous vinblastine infusion plus radiation therapy or surgery over RT alone for stage III limited, initially inoperable, non-small cell lung cancer [abstruct]. In Proceeding of the IV World Conference on Lung Cancer, Tronto, Canada, pp. 33, 1985.

• 10) Bitran, J. D., Golomb, H. M., Hoffman, P. C. etal:Protochemotherapy in non-small cell lung carcinoma. An attempt to increase surgical resectability and survival. A preliminary report. Cancer 57:44-53, 1986.
  pubmed

• 11) Takita, H., Regal, A. M., Antkowiak, J. G. et al:Chemotherapy followed by lung resection in inoperable non-small cell lung carcinomas due to locallyfar-advanced disease. Cancer 57:630-635, 1986.
  pubmed

• 12) Trybula, M., Taylor, S. G. Bonomi, P. et al:Preoperative simultaneous cisplatin/5-fluorouracil and radiotherapy in clinical stage III, non-small cell bronchogenic carcinoma [abstruct]. Proc. Am. Soc. Clin. Oncol 4:182, 1985.

• 13) Strauss, G., Sherman, D., Schwartz, J. et al:Combined mordality therapy for regionally advanced stage III non-small cell carcinoma of the Iung employing neoadjuvant chemotherapy, radiotherapy and surgery [abstruct]. Proc. Am. Soc. Clin. Oncol. 5:172, 1986.

• 14) Kris, M. G., Gralla, R. J., Martini, N. et al:Trial of pre-operative cisplatin plus vinca alkaloid chemotherapy in non-small cell lung cancer patients with clinically apparent, ipsilateral, mediastinal lymph node metastases [abstruct]. Proc. Am. Soc. Clin. Oncol. 6:177, 1987.

• 15) Hyde, L., Yee, J., Wilson, R. et al:Cell type and the natural history of lung cancer. JAMA 193:140-142, 1965.

• 16) Goldie, J. H., Coldman, A. J. and Gudanskas, G. A.:Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat. Rep. 66:439-449, 1982.

• 17) Prager, R. L., Foster, J. M, Hainsworth, LD. et al:The feasibility of adjuvant surgery in limited-stage small cell carcinoma:A prospective evaluation. Ann. Thorac. Surg. 38:622-626, 1984.

• 18) Meyer, J. A., Gullo, J. J., Ikins, P. M. et al:Adverse prognostic effect of N2 disease in treated small cell carcinoma of the lung. J. Thorac. Cardiovasc. Surg. 88:495-501, 1984.
  pubmed

P.134 掲載の参考文献

• 1) Yoneda, S., Honma, T., Yoshida, S. et al:Synergic effect of cisplatin, adriamycine, and cyclophosphamide combination chemotherapy and radiotherapy in non-small cell lung cancer. Oncol. 42:1-6, 1985.

• 2) Cox, J. D., Samson, M. K., Herskovic, A. M. et al:Cisplatin and etoposide befor definitive radiation therapy for inoperable squamous carcinoma, adenocarcinoma, and large cell carcinoma of the lung:A phase I-II study of the Radiation Therapy Oncology Group. Cancer Treat. Rep. 70:1219-1220, 1986.

• 3) Osoba, D., Rusthoven, J. J., Evans, W. K. et al:Combined chemotherapy and radiation therapy for non-small-cell lung cancer. Semin Oncol 13:121-124, 1986.
  pubmed

• 4) Blum, R. H., Cooper, J., Schmidt, A. M. et al:Cisplatin and vinblastine chemotherapy for matastatic non-small cell carcinoma followed by irradiation in patients with regional disease. Cancer Treat. Rep. 70:333-337, 1986.

• 5) Eagan, R. T., Ruud, C., Lee, R. E. et al:Pilot study of induction therapy with cyclo-phosphamide, doxirubicin and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III Mo non-small lung cancer. Cancer Treat. Rep. 71:895-900, 1987.

• 6) Friess, g. G., Baikadi, M. and Harvey, W. H.:Concurrent cisplatin and etoposide with radiotherapy in locally advanced non-small cell lung cancer. Cancer Treat. 71:681-684, 1987.
  pubmed

• 7) Harskamp, G., Boven, E., Vermorken, J. B. et al:Phase II trial of combined radio-therapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell cancer (NSCLG) . Int. Radiat. Oncol. Bio. Phys. 13:1735-1738, 1987.

• 8) Wils, J. A., Utama, I., Nause, A. et al:Phase II randomized trial of radiotherapy alone vs the sequential use of chemotherapy and radiotherapy in stage III non-small cell lung carcinoma. Phase ll trial of chemotherapy alone in stage IV non-small cell lung cancer. Eur. J. Cancer Clin. Oncol. 20:911-914, 1984.

• 9) Van Houtte, P., Klastersky, J., Nguyen, H. et al:Comparative randomized study of chest radiotherapy preceded or not by chemotherapy with cisplatin, etoposide and vindesine for the treatment of non-small cell lung cancer (NSCLC) Pro. ASCO. 25:785, 1984.

• 10) Trovo, M. G., Roncadin, M., Minatel, M. et al:End result of randomized study comparing radiotherapy (RT) and RT followed by CAMP regimen in patients with stage III epidermoid bronchogenic carcinoma. Pro. ASCO. 5:187, 1986.

• 11) Morton, R. F., Jett, J. R., Mher, L. et al:Randomized trial of thoratic radiation therapy (TRT) with or without chemotherapy for treatment locally unresectable non-small cell lung cancer (NSCLG) . Pro. ASCO. 7:200, 1988.

• 12) Dillman, R. O., Seagren, S. L., Propert, K. et al:Protochemotherapy improves survival in regional non-small cell lung cancer. Pro. ASCO. 7:195, 1988.

• 13) 宮本忠昭, 寺島東洋三:放射線と化学療法の併用. 癌放射線療法, 柄川順編, 篠原出版, p. 55, 1987.

• 14) 森田皓三:放射線治療と薬剤との併用. 癌と化学療法 14:1531-1537, 1987.
  Medical*Online

• 15) Simpson, J. R., Bauer, M., Wasserman, T. H. et al:Large fraction irradiation with or without misonidazole in advanced non-oat cell carcinoma of the lung:A phase III randomized trial of the RTOG. Int. J. Radiat. Oncol. Bio. Phys. 13:861-867, 1987.
  pubmed

• 16) Miyamoto, T. . Wakabayasi, M. and Terasima, T.:Aclarubicin (Aclacinomycin-A) and irradiation:Evaluation using Hela cells. Radiology 149:835-839, 1983.

• 17) Weiden, P.:Preoperative chemoradiotherapy in stage III non-small cell lung cancer (NS-CLG) . A phase II study of the lung cancer study group (LCSG) . Pro. ASCO. 6:185, 1987.

• 18) Sherman, D., Strauss, G., Schwartz, J. et al:Combined modality therapy for regionally advanced stage III non-small cell carcinoma of the lung employing neoadjuvant chemotherapy, radiotherapy and surgery. Pro. ASSO. 6:167, 1987.

• 19) Bonomi, P., Rowland, K., Taylor, S. G. et al:Phase II trial of etoposide, cisplatin, continuous infusion 5-fluorouacil, and simultaneous split-couse radiation therapy in stage III non-small-cell bronchogenic carcinoma. Semin. Oncol. 13:115-120, 1986.

• 20) Taylor, S. G., Trybula, M., Bonomi, P. et al:Simultaneous cisplatin, fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III, non-small cell lung cancer. Ann. Thorac. Surg. 43:87-91, 1987.
  pubmed

P.145 掲載の参考文献

• 1) Greco, F. A.:Seminars in Oncol. 13:92-96, 1986.

• 2) Rapp, E., Pater, J. L., Willan, A. et al:Chemotherapy can prolong survival in patients with advanced NSCLC-Report of a Canadian multicenter randomized trial. J. Clin. Oncol. 6:633-641, 1988.

• 3) Dillman, R. O., Seegren, S. L, Propert, V. et al:Protochemotherapy improves survival in regional non small cell lung cancer. Proc. of ASCO. 753, 1988.

• 4) Martini, N., Kris, M. G., Gralla, R. J. et al:The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases. (N2M0) . Ann. Thorac. Surg. 45:370-379, 1988.

• 5) Saijo, N., Shinkai, T., Eguchi, K. et al:Progress in chemotherapy for small and non-small cell lumg cancer in Japan. Proc. of first International Symposium of the Foundation for Promotion of Cancer Research (Fundamental and clinical research in lung cancer) pp. 54-55, 1988.

• 6) Saijo N, Shimizu E. Eguchi K. et al:Effect of peplomycin plus carbazilquinone and mitomycin C on non-small cell carcinoma of the lung. Cancer Treat. Rep. 67:385-387, 1983.
  pubmed

• 7) Shinkai T, Saijo N, Tominaga K. et al:Comparison of vindesine plus cisplatin or mitomycin in the treatment of advanced non-small cell lung cancer. Cancer Treat. Rep. 69:945-951, 1985.
  pubmed

• 8) Shinkai, T., Saijo, N, Eguchi, K. et al:Cisplatin and Vindesine combination chemotherapy for non-small cell lung cancer:A ramdomized trial comparing two dosages of cisplatin. Jpn. J. Cancer Res. (Gann) 77:782-789, 1986.

• 9) Shinkai, T., Saijo, N., Eguchi, K. et al:Comparison of the effect of vindesine (V) + cisplatin (P) vs V+P+ mitomycin C against non-small cell lung cancer. Proc. 5th Int. Cong. for lung Cancer, 1988.

• 10) 西脇 裕:私信

• 11) Gralla, J.:Personal communication.
  pubmed

• 12) Nomura. F. Shimokata, K., Saito, H. et al:Mitomycin C, vinblastine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 20:324-326, 1987.
  pubmed

• 13) 福岡正博, 根来俊一:進行非小細胞肺癌の化学療法. 医学のあゆみ 141:685-689, 1987.

• 14) Perry. M. C., Eaton, W. L, Propert, K. J. et al:Chemotherapy with or without radiation therapy in limited small cell carcinoma of the lung. New. Eng. J. Med. 316:912- 918, 1987.

• 15) Bunn, P. A., Lichter, A. S., Makuch, R. W. et al:Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. Ann. Int. Med. 106:655-662, 1987.

• 16) Yokota, J., Wada, M., Shimosato, Y. et al:Molecular genetic analysis of chromosome and oncogene abnormalities in lung cancer. Proc. the First International Symposium of the Foundation for Promotion of Cancer Research:Fundamental and Clinical Research in Lung Cancer, pp. 28-29, 1988.

• 17) Gazder, A. F., Fai, C. M., Park, J. G. et al:Neuroendocrine differentiation in non-small cell lung cancer. Incidence, biological properties and relative chemosensitivity Proc, of the First International Symposium of the Foundation for Promotion of Cancer Research Fundamental and Clinical Research in Lung Cancer, pp. 32-33, 1988.

• 18) Bork E., Hansen, M., Dombernovsky, P. et al:Teniposide (VM-26) an overlooked highly active agent in small cell lung cancer. Results of a phase II trial in untreated patients. J. Clin. Oncol. 4:527-527, 1986.

• 19) Tamura, T., Sasaki, Y., Eguchi, K. et al :Phase II trial of carbo platin on small cell lung cancer. Jpn. J. Clin. Oncol 18:27-32, 1988.

• 20) Aisner, J.:Identification of new drug in small cell lung cancer:Phase II agents first? Cancer Treat. Rep. 71:113-1134, 1987.

• 21) Aisner J.:Personal communication.

• 22) 中山治彦, 西條長宏:肺癌に対する neo-adjuvant chemotherapy. 治療 70:179-186, 1988.